本文關(guān)鍵詞： 細(xì)胞因子誘導(dǎo)的殺傷細(xì)胞 急性髓細(xì)胞白血病 老年 療效　出處：《安徽醫(yī)科大學(xué)學(xué)報(bào)》2017年03期 　論文類型：期刊論文

【摘要】：目的初步觀察及評(píng)價(jià)化療后細(xì)胞因子誘導(dǎo)的殺傷細(xì)胞(CIK)序貫治療老年急性髓系白血病(AML)患者的臨床療效,為老年AML患者建立新的副作用較小的維持治療方法。方法以5例多療程化療后疾病達(dá)緩解或部分緩解后難以繼續(xù)耐受化療的老年AML患者為研究對(duì)象,輔以自體CIK細(xì)胞序貫治療。觀察分析5例患者CIK細(xì)胞輸注后一般癥狀及不良反應(yīng),細(xì)胞免疫功能狀態(tài)、外周血微小殘留病變(MRD)水平、生活質(zhì)量評(píng)分(KPS)及生存期。結(jié)果 5例患者共接受35次CIK細(xì)胞回輸過程中均未出現(xiàn)不良反應(yīng),回輸后患者精神、食欲、體力等較前改善。CIK細(xì)胞治療后調(diào)節(jié)T細(xì)胞與效應(yīng)T細(xì)胞比例(2.70±1.59)較CIK細(xì)胞輸注前(5.35±5.50)明顯降低(P0.05)。CIK細(xì)胞治療后患者外周血MRD[(0.16±0.30)%]較CIK細(xì)胞治療前MRD[(0.86±0.84)%]明顯降低(P0.05)。CIK細(xì)胞輸注后患者KPS評(píng)分(88.8±6.03)較輸注前(75.45±10.35)改善(P0.05),平均總生存期29.8個(gè)月。結(jié)論本研究5例老年AML患者化療后自體CIK細(xì)胞序貫維持治療安全有效。
[Abstract]:Objective to observe and evaluate the clinical effect of cytokine-induced cytokine-induced cytokine-induced cytotoxicity (CIK) in elderly patients with acute myeloid leukemia (AML). To establish a new maintenance therapy for elderly patients with AML with less side effects. Methods five elderly patients with AML who had achieved remission or had difficulty in tolerating chemotherapy after more than one course of chemotherapy were studied. The general symptoms and adverse reactions, cellular immune function, and the level of minimal residual lesions in peripheral blood were observed and analyzed in 5 patients after CIK cell infusion, followed by sequential treatment with autologous CIK cells. Results there was no adverse reaction during 35 times of CIK cell transfusion in 5 patients. The ratio of regulating T cells to effector T cells (2.70 鹵1.59) was significantly lower than that of CIK cells (5.35 鹵5.50) after treatment. The level of MRD in peripheral blood of patients with CIK cells after treatment [0.16 鹵0.30%] was significantly lower than that of CIK cells [0.86 鹵0.84%]. The KPS score (88.8 鹵6.03) was better than that before infusion (75.45 鹵10.35). The average survival time was 29.8months. Conclusion Sequential maintenance of autologous CIK cells in 5 elderly patients with AML after chemotherapy is safe and effective.
【作者單位】： 安徽醫(yī)科大學(xué)第二附屬醫(yī)院血液科生物醫(yī)療研究中心安徽醫(yī)科大學(xué)血液病研究中心;
【基金】：國家自然科學(xué)基金(編號(hào):81401293) 安徽高校省級(jí)自然科學(xué)研究重大項(xiàng)目(編號(hào):KJ2014ZD17)
【分類號(hào)】：R733.71

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 何曉文;抗生素序貫治療106例兒童急性下呼吸道感染的成本-效果分析[J];廣西醫(yī)學(xué);2005年04期

2 霍蓓蓓;李昌崇;;小兒肺炎支原體肺炎序貫治療臨床分析[J];浙江臨床醫(yī)學(xué);2008年11期

3 董繼萍;文靜;;早期序貫治療對(duì)新生兒缺氧缺血性腦病預(yù)后的影響[J];中國婦幼保健;2010年34期

4 ;癌癥治療的新策略──放、化、切除聯(lián)合序貫治療的重要性[J];中華消化雜志;1998年04期

5 王明霞,孫玉忠;頭孢菌素序貫治療小兒社區(qū)獲得性肺炎療效觀察[J];山東醫(yī)藥;2005年10期

6 董繼萍;趙e，

本文編號(hào)：1512822